OMEROS CORP

OMER stock represents shares of Omeros Corporation, a biopharmaceutical company whose ticker symbol is OMER. It trades on the Nasdaq stock exchange. The company focuses on discovering, developing, and commercializing therapeutics for immunologic disorders, complement-mediated diseases, and other areas. Investors tracking OMER are typically following a clinical-stage and commercial-stage biopharma business, so company-specific news and trial updates often matter more than broad sector trends.

Recent performance for OMER depends on the latest market session and cannot be stated without current data. You can check the live price, daily change, and recent trend on the OMER stock page. For context, review the displayed performance over multiple periods, such as one week, one month, and year to date, to see how the shares have moved relative to the broader market.

The 52-week range shows the lowest and highest prices OMER has traded at over the past year. This figure changes as new highs or lows occur, so the exact values should be taken from the latest quote data on the page. The range can help investors gauge how volatile the stock has been and where the current price sits within its annual trading band.

Valuation for OMER is often assessed differently from mature companies because Omeros is a biopharmaceutical firm. Analysts may look at price-to-sales, price-to-book, cash position, pipeline value, and potential revenue from approved products. Traditional earnings-based measures like the P/E ratio may be less useful if the company is not consistently profitable. Compare these metrics with peers and review the latest financial statements for context.

OMER can be traded in pre-market and after-hours sessions through many brokers, though liquidity is typically lower than during regular Nasdaq hours. Extended-hours trading may involve wider spreads and greater price swings. Availability depends on your brokerage and the venue. Check your platform for OMER's extended session quote and any associated fees or limitations before placing an order.

OMER carries risks common to biopharmaceutical companies, including clinical trial failures, regulatory delays, reimbursement challenges, and dependence on key product candidates. Commercial execution and competition can also affect results. Financing risk matters if the company needs additional capital. Broader market, interest rate, and economic conditions can add volatility. Review OMER's SEC filings, especially risk factors, for a detailed discussion of company-specific uncertainties.